Lung Cancer: Targets and Therapy
Volume 14, 2023 - Issue
COMMENTARY
Stage as the Sole “Biomarker” for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?
Misako Nagasaka1 University of California Irvine School of Medicine, Orange, CA, USA;2 Chao Family Comprehensive Cancer Center, Orange, CA, USA;3 Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
https://orcid.org/0000-0001-5308-615X
https://orcid.org/0000-0001-5308-615X & Saihong Ignatius Ou1 University of California Irvine School of Medicine, Orange, CA, USA;2 Chao Family Comprehensive Cancer Center, Orange, CA, USACorrespondence[email protected]
https://orcid.org/0000-0002-1764-4975
https://orcid.org/0000-0002-1764-4975